Abu-Humaidan Anas H, Alajlouni Yazeed Y, Alajlouni Amin Y, Hamdan Omar F, Basyouni Batool L, Qasem Ola F, Riyalat Abdallah A, Hiasat Ruba I, Magharbeh Anmar H, Alaridah Nader
Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman, 11942, Jordan.
School of Medicine, Al-Balqa' Applied University, As-salt, 19117, Jordan.
BMC Infect Dis. 2025 Jul 26;25(1):945. doi: 10.1186/s12879-025-11358-8.
Patients with Diabetes mellitus (DM) have higher rates of urinary tract infections (UTIs). This study evaluated the antimicrobial resistance (AMR) of uropathogens and whether uropathogens isolated from DM patients exhibit greater AMR.
A cross-sectional multicenter study included adults with UTI symptoms and a positive urine culture from December 2020 to January 2021. Patients were categorized into uncomplicated UTI (G1, n = 133), complicated UTI without (G2, n = 215), or with DM (G3, n = 217). Patient data, microbiology results, and associations between DM, antibiotic resistance, and bacterial isolates were analyzed using Kruskal-Wallis followed by Dunn's multiple comparisons or Fisher's exact test, as appropriate.
E. coli from the complicated UTI groups G2 and G3 were resistant to more antibiotics and antibiotic classes, with a higher percentage of non- E. coli isolates than G1. The percentage of multidrug-resistant E. coli in G1, G2, and G3 was 30.5%, 61.8%, and 59.0%, respectively. In G1, resistance to fluoroquinolones and trimethoprim-sulfamethoxazole exceeded 20%, but remained below 20% for nitrofurantoin and fosfomycin. Although G2 and G3 had similar resistance profiles, differences occurred for specific antibiotics. E. coli from G3 exhibited higher resistance to nitrofurantoin (10.2% vs. 34.3%, p-value < 0.001) and piperacillin-tazobactam (31.3% vs. 16.6%, p-value = 0.061). In contrast, G2 Uropathogens had higher resistance to nalidixic acid, norfloxacin, and ofloxacin compared to G3.
These findings suggest a possible association between DM and the chance of recovering an isolate resistant to nitrofurantoin. Stratifying patients by risk factors like DM could improve empiric therapy outcomes and contribute to reducing AMR.
糖尿病(DM)患者尿路感染(UTIs)的发生率较高。本研究评估了尿路病原体的抗菌药物耐药性(AMR),以及从糖尿病患者中分离出的尿路病原体是否表现出更高的AMR。
一项横断面多中心研究纳入了2020年12月至2021年1月有尿路感染症状且尿培养呈阳性的成年人。患者被分为单纯性尿路感染组(G1,n = 133)、无糖尿病的复杂性尿路感染组(G2,n = 215)或有糖尿病的复杂性尿路感染组(G3,n = 217)。根据情况,使用Kruskal-Wallis检验,随后进行Dunn多重比较或Fisher精确检验,分析患者数据、微生物学结果以及糖尿病、抗生素耐药性和细菌分离株之间的关联。
复杂性尿路感染组G2和G3中的大肠杆菌对更多抗生素及抗生素类别耐药,非大肠杆菌分离株的比例高于G1组。G1、G2和G3中多重耐药大肠杆菌的比例分别为30.5%、61.8%和59.0%。在G1组中,对氟喹诺酮类和甲氧苄啶-磺胺甲恶唑的耐药率超过20%,但对呋喃妥因和磷霉素的耐药率仍低于20%。虽然G2和G3具有相似的耐药谱,但特定抗生素存在差异。G3组的大肠杆菌对呋喃妥因(10.2%对34.3%,p值<0.001)和哌拉西林-他唑巴坦(31.3%对16.6%,p值 = 0.061)的耐药性更高。相比之下,G2组的尿路病原体对萘啶酸、诺氟沙星和氧氟沙星的耐药性高于G3组。
这些发现表明糖尿病与分离出对呋喃妥因耐药菌株的可能性之间可能存在关联。根据糖尿病等危险因素对患者进行分层可以改善经验性治疗效果,并有助于降低AMR。